Full Press Release Details
Agenus R&D Day November 19, 2015
New York, NY Exhibit 99.1
Forward-Looking Statements This
presentation contains forward-looking statements, including statements regarding the Company's pending acquisition of XOMA Corporation's antibody pilot plant manufacturing facility and capabilities. These forward-looking statements are
subject to risks and uncertainties, including the factors described under the Risk Factors section of our Quarterly Report on form 10-Q filed with the Securities and Exchange Commission for the quarter ended September 30, 2015 and made available on
our website at www.agenusbio.com. When evaluating Agenus' business and prospects, careful consideration should be given to these risks and uncertainties. These statements speak only as of the date of this presentation, and Agenus
undertakes no obligation to update or revise these statements. This presentation and the information contained herein do not constitute an offer or solicitation of an offer for sale of any securities. Agenus R&D Day | Nov 19, 2015
Agenda Agenus R&D Day | Nov 19,
2015 Registration Agenus Strategy - Armen R&D Overview - Stein Immunomodulatory antibodies at Agenus - Wilson Next generation mAb discovery incorporating structure-based design - van Dijk, Underwood, Duncan Next Steps
with Prophage in ndGBM - Goldberg AutoSynVax : Next Generation Vaccines - Castle Wrap-up - Stein Q&A Reception
Agenus Strategy Garo Armen, PhD
Garo H. Armen, PhD Dr. Garo H. Armen
serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. From mid-2002 through 2004, Garo, in addition to his responsibilities at Agenus, served as Chairman of the Board of Directors for the biopharmaceutical
company Elan Corporation, which he successfully restructured. Garo serves as non-executive Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic
disorders. Dr. Armen received his PhD in Physical Chemistry from the City University of New York in 1979, and served as a science fellow at the Brookhaven National Laboratory. He transitioned to Wall Street and became a specialist in biotechnology
investing. Dr. Armen has authored a number of novel partnerships, including one between American Cyanamid with Immunex Corporation. He is also founder and Chairman of the Children of Armenia Fund (COAF), a philanthropic organization he founded in
2000. COAF implements programs to improve and advance all aspects of life for children living in rural villages of Armenia. Agenus R&D Day | Nov 19, 2015
Agenus: 6 months of progress May 14th
November 19th # of Partnered Programs 4 with Incyte 2 with Merck 7 with Incyte 2 with Merck* Capabilities 2 antibody platforms 4 antibody platforms Cell-line development Antibody manufacturing** Lead Programs Prophage 6 CPM programs
Prophage AutoSynVax 15 CPM Programs IND Filings None 2 within 30 days Cash*** $79m (March 31) $199m (September 30) * Extended collaboration term ** Subject to Xoma closing; expected December 2015 *** Includes cash, cash equivalents and
short term investments Agenus R&D Day | Nov 19, 2015
Positioned to create value for patients
and investors Autologous Vaccines Strong Financial Position CPM Assets to Enter Clinic Marquee Partnerships Broad & Integrated Capabilities Next Generation Programs Expanded Pipeline Planning Randomized Prophage Trials Core Foundation in
Immuno-Oncology Agenus R&D Day | Nov 19, 2015
ii. R&D Overview Agenus &
Immuno-Oncology: Enlisting the Immune System in the Battle against Cancer Robert B. Stein, MD, PhD CSO & Head of R&D
Robert B. Stein, MD, PhD As Chief
Scientific Officer and Head of R&D at Agenus Inc., Dr. Robert Stein is responsible for all aspects of R&D, including the antibody platforms. He joined Agenus in January 2014. Over his 35 years of experience in the biopharmaceutical industry
he played a pivotal role in bringing to the market Sustiva , Fablyn , Viviant , PanRetin , TargRetin , Promacta and Eliquis . Prior to joining Agenus he held a number of progressively responsible senior management
positions including CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto and CEO of KineMed. From 1981 to
1990, Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Agenus R&D Day | Nov 19, 2015
Advanced cancers are becoming
vulnerable to immune therapies! Agenus R&D Day | Nov 19, 2015 Control Standard or other therapy Checkpoint blockade Combination % Survival Time
Early recognition of role of immune
system in cancer control "It is by no means inconceivable that small accumulations of tumour cells may develop and because of their possession of new antigenic potentialities provide an effective immunological reaction with regression
of this tumor and no clinical hint of its existence." Sir F. Macfarland Burnet (1957) Why doesn't immuno-surveillance always protect us from cancer? How can we learn from nature & use immune mechanisms to treat cancers? Agenus
R&D Day | Nov 19, 2015
Mutations drive malignant
transformation - becoming cancerous Mutations Agenus R&D Day | Nov 19, 2015
Small fraction of mutations
immunologically detectable Various carcinogens (sun, smoke, gamma rays, etc.) produce stochastic mutations (<0.03% of genome) A fraction of these produce potential T-cell neo-epitopes - potential basis for immune rejection (1-20+) A handful
hit growth-related genes, driving malignancy (5-10) Approximately 1% of mutations produce mutant proteins Focus of targeted ChemoRx Basis for Immuno-therapy Agenus R&D Day | Nov 19, 2015
Lawrence MS et al. Nature 2013; 499:
214-18 Cancers are much more "self" than "non-self" In "highly mutant" tumors, <0.01% of the genome is mutant!! Agenus R&D Day | Nov 19, 2015
Median per tumor DNA Mutations can
produce "muteins" which can be neo-epitopes Agenus R&D Day | Nov 19, 2015 John Castle, Agenus unpublished data About 1% of point mutations encode mutant proteins About 5-10% of these are potential T-cell neo-epitopes These
neo-epitopes have the potential to trigger tumor rejection "Muteins"
The Problem - metaphorically
speaking - Aleksandr Solzhenitsyn, The Gulag Archipelago 1918-1956 "If only it were all so simple! If only there were evil people somewhere insidiously committing evil deeds, and it were necessary only to separate them from the
rest of us and destroy them. But the line dividing good and evil cuts through the heart of every human being. And who is willing to destroy a piece of his own heart?" How can we turn the immune system against cancer .. while sparing
normal tissues? Agenus R&D Day | Nov 19, 2015
Normal Transformed The immune system
versus cancer Agenus R&D Day | Nov 19, 2015
Normal Transformed The immune system
versus cancer X Immune Surveillance ELIMINATION by immune system Agenus R&D Day | Nov 19, 2015
Normal Transformed The immune system
versus cancer Select for Immune Resistance X Early Stage EQUILIBRIUM with immune system (dormancy) Immunoediting Agenus R&D Day | Nov 19, 2015
Agenus' HSP-based vaccines can
"wake the slumbering giant" Agenus R&D Day | Nov 19, 2015 Effectively enhancing immunity against tumor-specific neo-epitopes
The immune system & cancer -
survival of the stealthiest Strong immune selection exerted on cancer cells Cancers which could be recognized as "non-self" eliminated unless they evade immunity Avoid or blunt immune recognition Block destruction by immune mechanisms
Advanced cancers have defeated natural immunity Agenus R&D Day | Nov 19, 2015
Normal Transformed X Early Stage
Late Stage EQUILIBRIUM with immune system (dormancy) ESCAPE from immune system (progression) The immune system versus cancer Immuno-evasive adaptations Immunoediting Select for Immune Resistance
Immune response Immune regulation
through checkpoints Agenus R&D Day | Nov 19, 2015 T Cells and other Immune cells Inhibitory Receptors Checkpoints involve a range of receptors, usually on T-cells, activated by ligands on APCs or other cell types Checkpoint processes act to
tailor immune activity to need Time Resolution Inflammation Recognition Activating Receptors boosting responses initially then curbing them to prevent overshoot ceaCAM1
Cancers hijack checkpoint processes
to evade immunity Agenus R&D Day | Nov 19, 2015 T Cell Tumeh et al. Nature 515, 568-571 (27 November 2014) Inhibited antitumor immunity
Checkpoint modulating antibodies
(CPMs) reset the odds Agenus R&D Day | Nov 19, 2015 Tumeh et al. Nature 515, 568-571 (27 November 2014) Enhanced antitumor immunity
Choosing significant CP & CP-L
targets key to I-O success 7 Disclosed CPM programs 4 partnered with INCY 3 Agenus retained(*) 8 Undisclosed CPM programs 2 partnered with MRK 3 partnered with INCY (**) 3 Agenus retained PD-1 CTLA-4 LAG-3 OX-40 GITR B7-1/CD80SIRPa
BAFF/BLySCD200CD48/SLAMF2 B7-2/CD86CD47BAFF ROX-2R (CD200R)CD58/LFA-3 B7-H1/PD-L1LAIR-1 (CD305) RELTCD300a/LMIR1CD84/SLAMF5 B7-H2/B7RP1/ICOS-LBT3.1TACI CRTAMCD229/SLAMF3 B7-H3BT3.2TL1ADAP12CRACC/SLAMF7 B7-H4BT3.3TNRFSF25Dectin-1/CLEC7ANTB-A/SLAMF6
B7-H5/VISTA4-1BB/CD137TIGIT ( WUCAM, Vstm3)DPPIV/CD26 SLAM/CD150 CD284-1BB LigandCD155EphB6Integrin alpha 4 beta 1 ICOSCD27HLA-DRIntegrin alpha 4 beta 7/LPAM-1 PD-L2/B7-DCCD27 Ligand/CD70CD33IkarosTCL1A PDCD6CD30EP4 (PGE2 receptor)Integrin alpha
4/CD49dTCL1B B7-H6CD30 LigandNKG2DSiglec-5 (CD170)TIM-1/KIM-1/HAVCR B7-H7CD40GAL-9Siglec-7 (CD328)TIM-4 BTLA (CD272)CD40 LigandCD2ILT2TSLP KIRs HVEMCD7ILT4TSLP R DNAM-1 (CD226)LIGHTCD53EP2 (PGE2 receptor)A2AR
VSIG4DR3CD82/Kai-12B4/CD244/SLAMF4RNF125/TRAC-1 CD31 (PECAM-1)TNF-alphaCD90/Thy1BLAME/SLAMF8CD5 PILR-a (FDF03)TNF-betaCD96CD2MAFA PILR- TNF RIICD160CD2F-10/SLAMF9NKG2ANKG2B Over 100 potential checkpoint proteins TIM-3 CEACAM1 Agenus R&D Day
| Nov 19, 2015 (*) PD-1 and CTLA-4 are partnered with Recepta for certain South American territories (**) Recent Incyte alliance expansion
Tumors differ in the nature and
extent of non-self epitopes Immune system-tumor interaction varies between patients Immune system-tumor interactions evolve with time Immuno-editing, Checkpoints, other immuno-evasive or immuno-suppressive strategies A complex, redundant network of
processes shape immune system-tumor interactions Patient-specific immuno-monitoring essential Combination therapies - not "one-size-fits-all" - must be chosen to provide optimal patient benefit Agenus is poised to create
best-in-class combination therapeutic regimens for patients with cancer Agenus R&D Day | Nov 19, 2015 Combination therapies likely key to success in immuno-oncology
Agenus programs broadly address
therapeutic opportunities in I-O Modified Chen et al., 2013 Agenus R&D Day | Nov 19, 2015 Vaccines
Integrated Fast Flexible Scalable
Cost-effective Lead Generation Lead Optimization Drug Profiling IND Enabling Early Development Registrational Development Optimizing our monoclonal antibody (mAb) platform Phage Display GMP Production* Cell Line Dev. Retrocyte Display
Duobody HT-CHO Structure-Based Optimization Agenus R&D Day | Nov 19, 2015 * Subject to closing; expected December 2015 SECANT Yeast Display
Heat-Shock-Protein-based Cancer Vaccines QS21 Saponin Adjuvant Platform Monoclonal Antibody Platform & Capabilities Checkpoint Modulators Partnerships Pipeline Financials Prospects: best-in-class combination immuno-therapies Agenus 2.0 -
immuno-therapy re-envisioned Agenus R&D Day | Nov 19, 2015
iii. Immunomodulatory antibodies at
Agenus Nick Wilson, PhD Senior Director, T cell Biology
Nicholas Wilson, PhD Since August
2014, Nicholas Wilson has served as Agenus Inc.'s Senior Director, T Cell Biology. With over 10 years of industry-related research experience, Nicholas has led multi-functional teams of research and translational scientists focused on drug
discovery and development projects (EMD Serono, Novartis). Dr. Wilson has expertise in designing primary immune cell assays for the mechanistic evaluation of immune-based cancer therapies. Dr. Wilson is experienced in developing patient
stratification approaches and evaluating predictive pharmacodynamic biomarkers to enable personalized medicine. In addition, he has over 30 publications in high-impact research journals. Nicholas completed his postdoctoral fellowship at Genentech
Inc. (San Francisco, CA), and received his PhD in Immunology from the Walter and Eliza Hall Institute in Australia. Agenus R&D Day | Nov 19, 2015
Topics in focus Update on our
immuno-modulatory CPM antibody portfolio Combination opportunities with two distinct anti-CTLA-4 antagonist antibodies Next-generation Fc optimized immunomodulatory antibodies with improved function Harnessing our discovery antibody platforms to
target pathways involved in inflammation, transplantation and auto-immunity Agenus R&D Day | Nov 19, 2015
Immune & non-immune cells